Pay in 4 interest-free payments of $6.91 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
Relevant Studies & Resources For those interested in learning more about the research behind IGF-1, IGFBP-3, and their connection to cancer risk and hormone signaling, here are several peer-reviewed studies and academic resources: Circulating Growth Factor Concentrations and Breast Cancer Risk: A Nested Case-Control Study of IGF-1, IGFBP-3, and Breast Cancer in a Family-Based Cohort PMC Insulin-like Growth Factor (IGF)-I, IGF Binding Protein-3, and Cancer Risk: Systematic Review and Meta-Regression Analysis PubMed The Expression and Function of IGFBP-3 in Normal and Malignant Breast Tissue Anticancer Research IGF-1, IGFBP-3, and Cancer Risk The Lancet Concentrations of IGF-I and IGFBP-3 and Pancreatic Cancer Risk in the European Prospective Investigation into Cancer and Nutrition British Journal of Cancer Genetic Polymorphisms in the IGFBP3 Gene: Association with Breast Cancer Risk and Blood IGFBP-3 Protein Levels Among Chinese Women Cancer Epidemiology, Biomarkers & Prevention Plasma Levels of Insulin-Like Growth Factor-I and Lung Cancer Risk: A Case-Control Analysis Journal of the National Cancer Institute Alterations of Insulin-like Growth Factor Binding Protein 3 (IGFBP-3) Glycosylation in Patients with Breast Tumours Clinical Biochemistry
Our study also had some limitations
Vitale I, Pietrocola F, Guilbaud E, Aaronson SA, Abrams JM, Adam D, et al
:
)
Supplement labels recommend taking ZMA on an empty stomach approximately 3060 minutes before bed
Very Sweet Foods: High-sugar foods can sometimes trigger nausea
